N/A N=18 A Placebo-Controlled Effectiveness in INPH Shunting (PENS) Trial
Idiopathic Normal Pressure Hydrocephalus (INPH)
Primary: Change in Gait Velocity — 0.28; 0.04 meters per second — p=0.071
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=7 PET Imaging of Brain Amyloid in Normal Pressure Hydrocephalus
Normal Pressure Hydrocephalus
Primary: Quantitative Estimates of Brain Uptake [18F]Flutemetamol and the Quantitative Immunohistochemical (IHC) Estimates of Amyloid Levels in Biopsy Samples Previously…
N/A N=38 A Randomized Cross-over Study for Normal Pressure Hydrocephalus
Normal Pressure Hydrocephalus
Primary: Tinetti Score on Open Shunt vs. Closed Shunt — 24.50; 26.50 score on a scale
Phase 3 N=165 Idiopathic Intracranial Hypertension Treatment Trial
Idiopathic Intracranial Hypertension
Primary: Mean Change in Perimetric Mean Deviation — 1.43; 0.71 dB — p=0.05
N/A N=5 Non-invasive Estimation of CSF Pressure Using MRI in Patients With Spontaneous Intracranial Hypotension
Intracranial Hypotension
Primary: Intracranial Pressure Measurements Estimated by the MRICP Technique. — 6.5 cm H20
Phase 2 N=15 Treatment of Parkinson Disease and Multiple System Atrophy Using Intranasal Insulin.
Parkinson Disease · Multiple System Atrophy
Primary: Change in Verbal Fluency FAS (F, A or S Words) Total Score — 38.8; 41.0; 32.8; 30.8 Words
N/A N=37 Ventriculostomies in SAH: ICP Open or Not?
Subarachnoid Hemorrhage
Primary: Cerebral Artery Vasospasm — 16; 7 Participants
Phase 2 N=85 Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial)
Hypertension
Primary: Changes in Gray Matter Intracranial Pulsatility — -0.09; 0.02 mm/cardiac cycle
Phase 2 N=31 Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension.
Idiopathic Intracranial Hypertension
Primary: Intracranial Pressure — -0.3; -4.3 cmCSF
Phase 2 N=21 The Effects of Normalizing Blood Pressure on Cerebral Blood Flow in Hypotensive Individuals With Spinal Cord Injury
Spinal Cord Injury · Autonomic Dysreflexia · Baroreceptor Integrity
Primary: Systolic Blood Pressure — 93.21; 107.00; 95.8; 93.84 mmHg
N/A N=100 Optic Nerve Sheath Diameter (ONSD) With the Raised PCO2 and Internal Jugular Venous Occlusion
Elevated Intracranial Pressure (ICP)
Primary: Changes in ONSD in mm With Changes in ICP in Healthy Volunteers. — 4.2 mm
N/A N=30 Intra-Abdominal Hypertension in Neonatal Intensive Care Patients
Intra-Abdominal Hypertension
Primary: Intra-abdominal Pressure(IAP) Measurements in NICU Patients. — 1219 IAP measurements
N/A N=14 A Pilot Study of Optic Nerve Ultrasound Following Cardiopulmonary Bypass
Congenital Heart Disease · Congenital Heart Defect
Primary: Optic Nerve Sheath Diameter — 4.0; 3.6; 4.2; 3.5 millimeters
N/A N=91 Dementia With Lewy Bodies - Infinitome
Dementia With Lewy Bodies
Primary: Functional Connectivity Scores Between Pairs of Large Scale Brain Networks. — 0.164; 0.374; 0.344; 0.340 connectivity score
Phase 4 N=36 Determining the Prognostic Value of Continuous Intrathecal Infusion
Lumbar Post-Laminectomy Syndrome · Chronic Low Back Pain · Vertebral Compression Fracture
Primary: Change in Numerical Rating Scale Pain Scores (NRS) With Activity — 8.40; 8.00; 4.13; 4.19 Score on a scale
N/A N=5 Quantitative Characterization of Safe Irrigation for Ventricular Shunt Catheters
Hydrocephaly
Primary: To Demonstrate That the Flusher Can be Primed, Connected, and Activated in a Sterile Clinical Setting Per the Instructions for Use by the Treating Investigator . — 4; 4…
N/A N=23 Intracranial Pressure in Experimental Models of Headache
High Altitude Headache
Primary: Change in Optic Nerve Sheath Diameter by Ultrasonography — 0.02; 0.02 mm — p=0.98
N/A N=12 MRI for Non-invasive Evaluation of Brain Stress
Craniosynostosis
Primary: Blood Flow and Perfusion — 26.8 ml/min/100g — p=0.004
Phase 2 N=32 Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal
Parkinson's Disease
Primary: Number of Participants With Treatment Emergent Adverse Events — 5; 5; 3; 4 Participants
Phase 2 N=16 A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase®
Hunter Syndrome
Primary: Number of Serious Adverse Event (SAE) — 0; 8; 3; 3 events
N/A N=16 Vasopressin in Intraabdominal Pressure Elevation
Intracranial Pressure Increase · Abdominal Compartment Syndrome
Primary: Changes in Vasopressin Levels During Pneumoperitoneum and Elevated PEEP — 2.37; 45.48; 54.75; 31.57 pg/ml — p=<0.0001
Phase 4 N=163 Neurogenic Intermittent Claudication Evaluation Study
Spinal Stenosis
Primary: Mean Percentage Change From Baseline in Physical Function at 1 Year Follow-up Using the Patient Completed Zurich Claudication Questionnaire — -32.31; -37.48 percentage…
Phase 2 N=32 Phase 2 a Study to Assess Safety and Pharmacokinetics of VAS203 in Patients With Traumatic Brain Injury
Traumatic Brain Injury
Primary: Safety and Tolerability of VAS203 in Patients With Moderate and Severe TBI — 8; 8; 6; 8 participants
Phase 4 N=10 Cystagon to Treat Infantile Neuronal Ceroid Lipofuscinosis
Infantile Neronal Ceroid Lipofuscinosis
Primary: Change in Cellular Granular Osmiophilic Deposits (GRODs) in Electron Micrographs of Peripheral White Blood Cells. — -0.3317 Average number of GRODs
Phase 2 N=6 Intravenous Norepinephrine for Orthostatic Hypotension
Orthostatic Hypertension
Primary: Blood Pressure (Systolic) — 156; 158; 179; 148 mm Hg
N/A N=63 Intraoperative Ocular Pressure in Lumbar Spine Fusion Patients
Raised Ocular Pressure
Primary: Change in Intraoperative Ocular Pressure in Lumbar Spine Fusion Patients Head Raised 10 Degrees or Kept in Neutral Position — 9.26; 13.79 mm Hg
N/A N=199 Intensive Versus Standard Blood Pressure Lowering to Prevent Functional Decline in Older People
Hypertension, Systolic · Cerebrovascular Disease
Primary: Mobility - Measured by Change in Gait Speed — 0.4; 0.42 seconds
Phase 2 N=21 Feasibility of an Integrated Patient Care (IPC) System Using Daily Filling Pressures
Heart Failure
Primary: Characterize the Technical Feasibility of the Network Based IPC System — 72 percentage of days
Phase 2 N=30 Enhancement of Cerebral Vasoreactivity and Cognition by Intranasal Insulin in Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Cognitive Outcome: Brief Visuospatial Spatial Memory Test -Total Recall (Unit T Score) — 39.46; 41.23; 43.1; 50.9 T-score
N/A N=162 Posterior Fossa Decompression With or Without Duraplasty for Chiari Type I Malformation With Syringomyelia
Arnold-Chiari Malformation, Type 1 · Chiari Malformation Type I · Type I Arnold-Chiari Malformation
Primary: The Number of Participants With Surgical Complications — 8; 10 Participants